scispace - formally typeset
E

Elsa Iannicelli

Researcher at Sapienza University of Rome

Publications -  82
Citations -  1262

Elsa Iannicelli is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 17, co-authored 74 publications receiving 934 citations. Previous affiliations of Elsa Iannicelli include Policlinico Umberto I.

Papers
More filters
Journal ArticleDOI

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

TL;DR: Distant extra-hepatic metastases are the major predictor of poor efficacy of somatostatin analogues in progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinomas and should be considered for alternative treatments.
Journal ArticleDOI

Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients.

TL;DR: Symptoms correlate to tumor location, to class risk criteria as mitotic index and risk classifications, however it cannot be concluded that symptoms are per se predictive of survival or patient's outcome.
Journal ArticleDOI

Evaluation of bifid median nerve with sonography and MR imaging.

TL;DR: The correlation between ultrasonographic findings and magnetic resonance imaging results in six patients with bifid median nerve, selected from a population of 294 patients with carpal tunnel syndrome, who were studied by ultrasonography using a high frequency transducer is reported.
Journal ArticleDOI

Tubercular epididymitis and orchitis: US patterns

TL;DR: The aim of this pictorial essay is to provide an outline of the typical US images of tubercular epididymitis and orchitis.
Journal ArticleDOI

Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome.

TL;DR: The stratification of stage IV NET patients based on metastatic patterns, alongside Ki67, predicts the clinical outcome, and the extent of metastatic disease is a previously unrecognized variable, which should be considered when evaluating the results of treatments in NET patients with advanced disease.